Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.61 |
| ▸ | ITGAV | P06756 | 19/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.41 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024060 | 0.89 | ITGB3 (0.73) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5025667 | 0.88 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5026377 | 0.85 | ITGB3 (0.80) | ITGB3ITGAV | |
| SCHEMBL6424509 | 0.85 | ITGB3 (0.64) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5028147 | 0.83 | ITGB3 (0.79) | ITGB3ITGAV | |
| SCHEMBL5025631 | 0.80 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5028344 | 0.80 | ITGB3 (0.74) | ITGB3ITGAV | |
| SCHEMBL5023982 | 0.79 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5024005 | 0.78 | ITGB3 (0.79) | ITGB3ITGAV | |
| SCHEMBL5025430 | 0.78 | ITGB3 (0.68) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1286673-B1 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885ITGA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.